永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

交易中 12-30 10:51:43

2.850

+0.050

+1.79%

最高2.880	最低2.800	成交量21.60万
今开2.800	昨收2.800	日振幅2.86%
总市值17.61亿	流通市值17.61亿	总股本6.18亿
成交额61.21万	换手率0.03%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":2.85,"timestamp":1767061433423,"preClose":2.8,"halted":0,"volume":216000,"delay":0,"floatShares":618000000,"shares":618000000,"eps":-0.4034816852829778,"marketStatus":"交易中","change":0.05,"latestTime":"12-30 10:51:43","open":2.8,"high":2.88,"low":2.8,"amount":612060,"amplitude":0.028571,"askPrice":2.85,"askSize":4000,"bidPrice":2.83,"bidSize":12000,"shortable":0,"etf":0,"ttmEps":-0.4824631399217602,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1767067200000},"marketStatusCode":2,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":2.8,"openAndCloseTimeList":[[1767058200000,1767067200000],[1767070800000,1767081600000]],"volumeRatio":0.631432,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2595784432","title":"奥赛康最新公告：奥赛康药业与阿诺医药达成1类创新药AN9025项目许可引进协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784432","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784432?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:59","pubTimestamp":1767005993,"startTime":"0","endTime":"0","summary":"奥赛康公告称，公司子公司奥赛康药业与阿诺医药达成许可引进协议，将获得阿诺医药在研的1类创新药AN9025项目在许可区域内的开发、生产及商业化的独占权益。奥赛康药业将向阿诺医药支付与若干销售里程碑事件达成相关的付款，总计不超过11.28亿元人民币。AN9025项目为新型口服泛RAS抑制剂，用于治疗RAS突变型实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900029021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0028","002755","159992","BK1574","BK0239","BK1161"],"gpt_icon":0},{"id":"2595789267","title":"京新药业：LP（a）降脂创新药临床I期接近尾声","url":"https://stock-news.laohu8.com/highlight/detail?id=2595789267","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595789267?lang=zh_cn&edition=full","pubTime":"2025-12-29 18:09","pubTimestamp":1767002953,"startTime":"0","endTime":"0","summary":"证券之星消息，京新药业12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：京新药业的 JX2201 目前处于 I期临床末尾，临床指标是不是达到预期效果，目前公司有没有准备启动2期临床的计划。同时请问公司这款创新药在国内同行业中属于第几梯队在国际上属于什么层次？公司的LP降脂创新药临床I期接近尾声，盐酸卡利拉嗪胶囊已提交上市申请，正常推进中，具体情况敬请关注定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122900025460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","002020","BK0239","159992","BK1161","BK1574"],"gpt_icon":0},{"id":"2595788890","title":"海翔药业(002099.SZ)参投公司创新药NWRD06注射液完成Ⅱ期临床首例受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2595788890","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595788890?lang=zh_cn&edition=full","pubTime":"2025-12-29 16:11","pubTimestamp":1766995885,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海翔药业 发布公告，公司近日收到旗下产业基金管理人北京国信中数投资管理有限公司出具的《通知函》。NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK0028","BK0077","BK0192","BK1161","159992","BK0188","BK1574","BK0239","002099"],"gpt_icon":0},{"id":"2595673500","title":"国产银屑病创新药密集突破！正大天晴重磅1类新药2期临床取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2595673500","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595673500?lang=zh_cn&edition=full","pubTime":"2025-12-29 15:00","pubTimestamp":1766991624,"startTime":"0","endTime":"0","summary":"如中国生物制药于12月29日宣布，正大天晴自主研发的1类创新药TQH3906用于中重度斑块状银屑病的二期临床试验，达到主要研究终点。除了在研药物的稳步推进，国内还有多款治疗中重度斑块状银屑病的创新药已经获批上市。国产银屑病创新药的密集突破，不仅打破了此前临床治疗对进口药物的依赖，更推动我国银屑病治疗进入精准靶向的新时代。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229150230a6dbeecd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251229150230a6dbeecd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1161","BK1574","09926","LU2543165471.USD","BK1191","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","LU1023057109.AUD","06978"],"gpt_icon":0},{"id":"2595206531","title":"商保创新药目录出台后：“三除外”能否跑通？会否重演国谈药进院难？","url":"https://stock-news.laohu8.com/highlight/detail?id=2595206531","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595206531?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:46","pubTimestamp":1766979960,"startTime":"0","endTime":"0","summary":"自12月7日国家医保谈判结束，次日四川省即印发基本医保目录、商业健康保险创新药目录的挂网采购通知。对于首次发布的商业健康保险创新药目录，业界更为关心的，是该目录纳入的19种高值创新药接下来将如何“闯三关”，也即进院、开方、支付这三道真正的难关。　　但目前尚无明确的细则，指导“三除外”政策落地。　　商保目录出台后，“三除外”如何实现，商保创新药是否会遭遇与早年国谈药相似的进院困境？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxyy/2025-12-29/doc-inhemqaw5053913.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","06978","BK1161","159992"],"gpt_icon":0},{"id":"2595053262","title":"跨国药企发起降价潮？港股通创新药逆市走低，520880溢价高企！机构力挺国产创新药：重点关注2026年Q1","url":"https://stock-news.laohu8.com/highlight/detail?id=2595053262","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595053262?lang=zh_cn&edition=full","pubTime":"2025-12-29 11:07","pubTimestamp":1766977620,"startTime":"0","endTime":"0","summary":"12月29日，港股开市走高，恒指飘红，恒科指一度涨超2%。普涨之下，创新药板块意外走低，港股通创新药ETF盘中跌逾1.5%，权重股石药集团跌逾2%，康方生物、中国生物制药等龙头股均跌逾1%。　　不过港股通创新药ETF场内持续溢价交易，显示或有低吸资金逢跌吸筹。　　消息面，2025年年末，一场由跨国药企诺和诺德与礼来主动发起的降价潮，在政府采购平台、电商平台悄然上演，实际成交价格较半年前近乎“腰斩”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-29/doc-inhemqas7995635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","06978","BK1574","520880","BK1161"],"gpt_icon":0},{"id":"2594227549","title":"翰森制药引入透析领域创新药 深化肾科领域布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2594227549","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594227549?lang=zh_cn&edition=full","pubTime":"2025-12-28 19:44","pubTimestamp":1766922269,"startTime":"0","endTime":"0","summary":"格隆汇12月28日｜翰森制药(3692.HK)宣布订立许可协议，获得创新药SHR6508于中国(不含港澳台)的独家开发、生产和商业化权益。据悉，SHR6508为钙敏感受体(CaSR)变构调节剂，目前处于Ⅲ期临床试验阶段，拟用于治疗需接受血液透析的慢性肾脏病(CKD)成年患者的继发性甲状旁腺功能亢进症。值得注意的是，翰森制药已于2023年上市一款肾科领域创新药圣罗莱®(培莫沙肽注射液)，用于治疗肾性贫血，且已在肾脏病和透析领域拥有成熟的商业化体系和市场准入能力。本次合作标志着翰森制药进一步深化肾科产品布局，持续提升核心竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228194507a6d903b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228194507a6d903b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1191","BK1574","BK1589","03692","06978","BK1583"],"gpt_icon":0},{"id":"2594222159","title":"原料药企转创新药5大样本：华海、博瑞、昂利康、联邦和亿帆药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2594222159","media":"药事纵横","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594222159?lang=zh_cn&edition=full","pubTime":"2025-12-28 08:05","pubTimestamp":1766880305,"startTime":"0","endTime":"0","summary":"本次我们将围绕华海药业、博瑞医药、昂利康、联邦制药、亿帆药业这五家转型姿态鲜明、路径各异的代表性公司，一起来探索他们的转型之路。华海药业与博瑞医药净利润出现较大下滑，但研发投入持续加码。昂利康利润增长亮眼，研发投入1.22亿，同比减少25%。表来源：昂利康2025半年度报告联邦制药和亿帆药业则都是平稳增长的态势，其中联邦制药收与净利润均保持正增长，研发费用同步提升11.67%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228080837a4805ded&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228080837a4805ded&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","03933","06978","BK1191"],"gpt_icon":0},{"id":"2594326242","title":"每周股票复盘：联环药业（600513）创新药LH-1801预计2026年一季度揭盲","url":"https://stock-news.laohu8.com/highlight/detail?id=2594326242","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594326242?lang=zh_cn&edition=full","pubTime":"2025-12-28 03:35","pubTimestamp":1766864112,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，联环药业报收于18.3元，较上周的17.98元上涨1.78%。本周，联环药业12月26日盘中最高价报18.48元。联环药业于2025年12月22日召开2025年第三季度业绩说明会，管理层回应投资者关切，表示持续推进呼吸系统、肿瘤、内分泌等领域创新药研发，多个项目处于临床阶段，其中LH-1801预计2026年一季度揭盲。创新药LH-1801处于III期临床52周随访阶段，预计2026年一季度揭盲。该药品用于治疗成人原发性高血压，2024年度全国样本医院销售额为5,873.19万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600513","159992","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2594224077","title":"医药行业周报：JPM2026前瞻：看好中国企业技术突破和国际化机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2594224077","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594224077?lang=zh_cn&edition=full","pubTime":"2025-12-28 00:00","pubTimestamp":1766851200,"startTime":"0","endTime":"0","summary":"核心观点：第44届J.P.摩根医疗健康大会将于2026年1月12日至15日在旧金山举行，预计吸引超8000名全球参与者。中国医药具有“创新升级+ 供应链韧性”优势，2025年前三季度创新药海外授权超去年全年，器械也在积极探索出海路径。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228183730a481d77e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251228183730a481d77e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320764599.SGD","02269","LU0052750758.USD","LU1880383366.USD","LU0456827905.SGD","LU0307460666.USD","LU0588546209.SGD","LU0348825331.USD","SG9999002562.SGD","LU0417516738.SGD","LU0359201612.USD","LU0979878070.USD","SG9999002463.SGD","LU0326950275.SGD","LU0516422366.SGD","LU3063872942.SGD","LU0856984785.SGD","06978","BK1576","LU0043850808.USD","LU0140636845.USD","LU1688375341.USD","LU0823426308.USD","BK1610","LU0516423091.SGD","LU1242518931.SGD","BK1589","BK1521","IE00B0JY6N72.USD","LU0327786744.USD","LU0572944931.SGD","LU0456846285.SGD","LU1242518857.USD","BK1161","LU0417516902.SGD","06855","LU0708995583.HKD","LU0516422952.EUR","LU2039709279.SGD","LU0359202008.SGD","LU0516422440.USD","LU0039217434.USD","01801","LU0819121731.USD","LU0181495838.USD","LU0348735423.USD","LU1794554557.SGD","BK1141","LU0823426480.USD","LU0051755006.USD","LU0516423174.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"2594226457","title":"创新药BD热后，估值“还债”中","url":"https://stock-news.laohu8.com/highlight/detail?id=2594226457","media":"药闻社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594226457?lang=zh_cn&edition=full","pubTime":"2025-12-27 20:00","pubTimestamp":1766836823,"startTime":"0","endTime":"0","summary":"彼时，市面上甚至还有好几只年内收益翻倍的医药主题基金，BD交易频频刷屏，许多人都相信，“创新药的黄金十年”在二级市场上正在兑现。不少头部及腰部创新药企在年末连续发布了重磅的BD达成公告，交易对象不乏阿斯利康、武田、百时美施贵宝等全球制药巨头，但二级市场的反馈却时常冷淡，股价屡屡出现见光死的行情，市场情绪从期待转为疲软。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1161","01093","BK1574","02509","06978"],"gpt_icon":0},{"id":"2594262003","title":"突破创新药研发瓶颈，谁将为人类赢得下一场生命之战？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594262003","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594262003?lang=zh_cn&edition=full","pubTime":"2025-12-26 15:51","pubTimestamp":1766735460,"startTime":"0","endTime":"0","summary":"　　“为中国经济点赞——企业家之夜”已于12月17日正式启动，目前点赞活动正在火热进行中。　　在科技飞速发展的当下，创新药研发作为生命科学领域的关键战场，承载着人类对抗疾病、追求健康的美好愿景。药明康德董事长李革、江苏恒瑞医药董事长孙飘扬、康方生物主席夏瑜、百利天恒药业董事长朱义，谁将为人类赢得下一场生命之战？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-12-26/doc-inhecipr0850194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","159992","06978"],"gpt_icon":0},{"id":"2594193261","title":"长城基金梁福睿：2026年创新药行情值得期待","url":"https://stock-news.laohu8.com/highlight/detail?id=2594193261","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594193261?lang=zh_cn&edition=full","pubTime":"2025-12-26 14:57","pubTimestamp":1766732220,"startTime":"0","endTime":"0","summary":"近日，长城基金举办了2026年度投资策略会，长城医药产业基金经理梁福睿在会上就创新药领域的热门问题展开了深度探讨。　　展望2026年，梁福睿依旧看好创新药行情。梁福睿认为，2026年创新药有望兼具Beta和Alpha，是双层共振的方向。叠加2026年全球流动性环境可能总体宽裕，以及自身产业趋势加持、Alpha变化支撑，明年创新药值得期待。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-12-26/doc-inheccft0928983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK0196","03692","02096","BK0060","688062","603087","BK0183","BK1161","LU2580892862.HKD","LU0405327494.USD","LU2097828805.USD","BK0028","LU2097828557.USD","LU1328615791.USD","01530","LU1146622755.USD","688336","09995","688428","01167","LU2488822045.USD","LU2097828714.EUR","600276","LU0405327148.USD","BK1589","002755","LU1781817850.SGD","000661","LU1997245177.USD","LU1997245094.SGD","LU1064131003.USD","LU2097828474.EUR","BK0057","BK0012","BK1574","LU2097828631.EUR","06978","LU2148510915.USD","02509","BK0239","02142","LU1997244956.HKD","BK0188","LU0502904849.HKD","688331","LU1064130708.USD","LU2495084118.USD","LU1969619763.USD","01801"],"gpt_icon":0},{"id":"2594284633","title":"翰思艾泰港交所上市首日大跌30%！5.9亿港元融资押注肿瘤免疫与ADC创新药，HX009领衔多管线布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2594284633","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594284633?lang=zh_cn&edition=full","pubTime":"2025-12-25 12:00","pubTimestamp":1766635251,"startTime":"0","endTime":"0","summary":"图源：摩熵医药数据库-全球药物研发数据库公司的定位是提供新一代肿瘤免疫治疗，如HX009、HX044及HX016，以对抗PD-1抗性；提供一流的ADC分子HX111，以精确治疗特定恶性肿瘤；以及提供新型自身免疫治疗，如BsAb双功能抗体HX035及HX038。2023年、2024年和2025年前八个月，翰思艾泰研发开支分别为人民币4,666.3万、7,472.1万和5,617.8万元；净亏损分别为人民币0.85亿、1.17亿和0.88亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","06978","03378","BK1161","BK1173","BK1535"],"gpt_icon":1},{"id":"2594928361","title":"中国创新药“闯关”海外市场，如何实现全球价值兑现？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594928361","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594928361?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:21","pubTimestamp":1766622108,"startTime":"0","endTime":"0","summary":"从长期来看，中国创新药市场规模有望持续增长，到2030年，中国创新药行业市场规模将接近2.3万亿元。完成审评5848个品种，同比增长9.49%；共计批准创新药上市54个品种。BD“造血”其实，2025年中国创新药行业最显著的特点，就是BD交易从“火热”到“价值兑现”的实质性跨越。这显示出中国创新资产在全球定价权的重要地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225082633a4751dd5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225082633a4751dd5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02142","BK1161","01801","01530","BK1574","01276","02615","06978"],"gpt_icon":0},{"id":"2593477930","title":"国内商保发展和集采优化 创新药产业链持续活跃","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477930","media":"金证研","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477930?lang=zh_cn&edition=full","pubTime":"2025-12-24 21:11","pubTimestamp":1766581900,"startTime":"0","endTime":"0","summary":"随着国内商保发展和集采优化，创新药产业链高景气有望延续。当前支持创新药产业发展已成为政策导向，2025年北京、上海、重庆、四川等多地出台相关政策，推动创新药行业高质量发展。近日，2026年医保药品目录和商保药品目录发布，首次在基本医保目录之外增设商保创新药目录。创新药长期产业趋势确定，在国内政策支持以及美联储进入降息周期的背景下，全球创新药研发持续活跃，2026年还有大量BD落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224211713a6ca8bf6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1961090484.USD","01801","LU1720050803.USD","LU0348825331.USD","LU2778985437.USD","LU0348767384.USD","BK1574","01276","LU0417516738.SGD","LU0348784397.USD","06978","LU2488822045.USD","LU0348735423.USD","BK1161","IE00BPRC5H50.USD","01877","IE00B543WZ88.USD","09926","LU0348827113.USD","LU0417516571.SGD","LU0634319403.HKD","LU0348766576.USD","LU2399975544.HKD","LU2476274308.USD","ONC","LU0417516902.SGD","LU0540923850.HKD","LU1794554557.SGD","LU0348783233.USD","LU2476274720.SGD","IE00B5MMRT66.SGD","LU0561508036.HKD"],"gpt_icon":0},{"id":"2594940718","title":"抗流感创新药正面交锋：玛巴洛沙韦护城河有多宽？","url":"https://stock-news.laohu8.com/highlight/detail?id=2594940718","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594940718?lang=zh_cn&edition=full","pubTime":"2025-12-24 19:55","pubTimestamp":1766577331,"startTime":"0","endTime":"0","summary":"2025年流感季来袭，全国目前共有17个省份病毒活动仍处于高位流行水平。结果显示：流感感染者单次玛巴洛沙韦后，其未接受治疗的家庭成员感染病毒的概率降低32%。这无疑证明玛巴洛沙韦在健康、儿童或并发症高风险人群中的临床获益。品牌和口碑需要时间累积目前国内抗流感药物市场，依然是奥司他韦和玛巴洛沙韦的天下。2021年，玛巴洛沙韦获批上市，目前已进入医保目录。2024年流感季，玛巴洛沙韦曾一度断货。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224195909a6ca4994&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224195909a6ca4994&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","BK1574","BK1191","06978","BK1161"],"gpt_icon":0},{"id":"2593422894","title":"优宁维：创新药研发是公司产品主要应用领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422894?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:05","pubTimestamp":1766559928,"startTime":"0","endTime":"0","summary":"证券之星消息，优宁维(301166)12月24日在投资者关系平台上答复投资者关心的问题。投资者提问：祁总，公司有没有向创新药或者脑机接口进军布局？优宁维回复：投资者您好，公司主要面向国内高等院校、科研院所、医院和生物医药企业等科研端，提供生命科学试剂、设备、耗材、综合技术服务等产品和服务。创新药研发是公司产品的主要应用领域之一。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK0250","301166","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"2593213634","title":"审批进度加快，年末多款创新药集中获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2593213634","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593213634?lang=zh_cn&edition=full","pubTime":"2025-12-24 13:56","pubTimestamp":1766555761,"startTime":"0","endTime":"0","summary":"江海证券研报认为，此次“四连发”不仅是审评审批效率的体现，更标志着中国创新药研发成果迎来一轮密集的上市收获期。2024年，我国有48个创新药获批上市。此前的12月7日，国家药监局党组成员、副局长杨胜对外表示，今年以来，中国批准上市的创新药，截至当天，达到69个，已经超过了去年全年，再次创造了历史新高。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224135811953b98c3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161","09688","LU2488822045.USD","06978","BK1588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":-0.0759},{"period":"3month","weight":-0.4215},{"period":"6month","weight":-0.0345},{"period":"1year","weight":0.2444},{"period":"ytd","weight":0.2174}],"compareEarnings":[{"period":"1week","weight":-0.0065},{"period":"1month","weight":-0.0086},{"period":"3month","weight":-0.0454},{"period":"6month","weight":0.0584},{"period":"1year","weight":0.276},{"period":"ytd","weight":0.2779}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括EAL和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.065686},{"month":2,"riseRate":0.6,"avgChangeRate":0.206387},{"month":3,"riseRate":0.4,"avgChangeRate":-0.092735},{"month":4,"riseRate":0.2,"avgChangeRate":-0.078794},{"month":5,"riseRate":0.4,"avgChangeRate":-0.038349},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.060518}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}